Home  /  Regulatory Affairs
Regulatory Affairs · Submission Documents

Regulatory Writing Services

Regulatory writing turns your clinical, non-clinical, and quality data into the structured submission documents that health authorities expect, written to international standards and ready for review. Our regulatory writing services support pharmaceutical, biotech, and diagnostics companies preparing dossiers for India's CDSCO, the US FDA, the European EMA, and Middle East regulators. We author clear, consistent, submission-ready documents that help your application move through review with fewer queries.

CTD & eCTDModule 2 summariesICH guidanceCDSCO, FDA & EMA
Dossier · Build
Source dataCSRs, non-clinical, and quality data
CTD structureModules mapped to the authority
Module 2 summariesOverviews and written summaries
Submission readyOne coherent scientific argument
The Pathway

What regulatory writing covers

Regulatory writing spans the full Common Technical Document (CTD) and its electronic format (eCTD). Every document is built around the relevant ICH guidance and the specific expectations of your target authority, so your dossier reads as one coherent, defensible scientific argument rather than a collection of separate reports.

Module 2 summaries

The Clinical Overview, the Non-Clinical Overview, and the written and tabulated summaries that condense your evidence for the reviewer, alongside the Quality Overall Summary.

Clinical OverviewNon-Clinical OverviewQOS

Briefing and meeting documents

Briefing documents for scientific advice and pre-submission meetings, and meeting requests that keep a submission on track.

Regulatory responses

Answers to authority queries and deficiency letters, written to close the question rather than restate the data.

India-specific support

Submission support under the New Drugs and Clinical Trials Rules, 2019, including Form CT-04 and related dossier components.

NDCT 2019Form CT-04
At a Glance
ScopeCTD and eCTD documents
Module 2Clinical and Non-Clinical Overviews
StandardsCurrent ICH guidance
AuthoritiesCDSCO, FDA, EMA, Middle East
India frameworkNDCT Rules, 2019
ApproachClinician-led

Who it is for: sponsors, CROs, generic and biosimilar manufacturers, and diagnostics companies who need experienced regulatory authoring without building a permanent in-house team. We plug in at document level or across a full submission.

Deliverables

What we prepare

Module 2 summariesClinical Overview, Non-Clinical Overview, Clinical Summary, and Quality Overall Summary.

Briefing documentsFor scientific advice and pre-submission meetings.

Study summariesClinical and non-clinical summaries for inclusion in regulatory dossiers.

Regulatory responsesAnswers to authority queries and deficiency letters.

Investigator's BrochuresIBs and updates, alongside the protocol and safety documents.

India submission supportUnder the NDCT Rules, 2019, including Form CT-04 and related components.

Partnership

How EvySaif helps

We author clear, consistent, submission-ready documents from your existing data, working to current ICH guidance and aligning each document to your target market. Whether you are filing your first application or scaling a pipeline, we plug in at document level or across a full submission.

Author Module 2 summaries and overviews from your data
Align each document to the target authority
Keep language consistent across the dossier
Plug in at document level or across a full submission

Why EvySaif

EvySaif is one of the best research and medical writing consultancies in India, and we bring that standard to every project. Our regulatory writing is clinician-led, which means your documents are reviewed by someone who understands the clinical substance, not just the format. We work to current ICH guidance and align each document to your target market, whether that is India, the GCC, the EU, or the US, and we deliver at consultancy pricing that suits emerging and mid-size sponsors.

Questions

Frequently asked questions

Medical writing is the broader discipline. Regulatory writing is the subset focused specifically on documents submitted to health authorities, such as CTD modules, dossier summaries, briefing documents, and regulatory correspondence. EvySaif offers both.

Yes. We prepare dossier components aligned with the New Drugs and Clinical Trials Rules, 2019, and the CTD structure CDSCO expects, alongside FDA, EMA, and Middle East submissions.

Yes. We author summaries and overviews directly from your CSRs, non-clinical reports, and quality data, keeping language consistent across the dossier.

Have a different question?

Tell us about your product, market, and timeline, and a clinician on our team will reply with specifics rather than a sales script.

Request a proposal
Last updated: July 2026. Regulatory forms, portals, and timelines change; specifics are re-verified periodically.

Planning a submission?

Tell us about your product, target market, and timeline, and we will come back with a scoped regulatory writing quote.

Request a proposal